NCT04375150View on ClinicalTrials.gov

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

CompletedOBSERVATIONAL
Enrollment

355

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions
Renal Cell Carcinoma (RCC)
Interventions
DRUG

Tyrosine kinase inhibitor (TKI)

TKIs

DRUG

Immuno-oncology (IO)

IOs

Trial Locations (1)

10017

Pfizer INC, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY